Alisol A 24-Acetate Isolated from the Alismatis Rhizoma Improves Hepatic Lipid Deposition in Hyperlipidemic Mice by ABCA1/ABCG1 Pathway.
The Alisol A 24-acetate is an effective component of the Alismatis Rhizoma (AR) extract, which is often used in the treatment of hyperlipidemia. This study explored the effect and mechanism of the Alisol A 24-acetate from AR on lipid deposition in the liver of hyperlipidemic mice. After establishing hyperlipidemic mouse model (Model) by oral high-fat diet (HFD), the animals were treated with Alisol A 24-acetate for 4 weeks. The changes of blood lipid in mice were detected by ELISA. Hematoxylin and eosin (H&E) staining was used to evaluate the degree of liver lipid deposition in hyperlipidemic mice. Quantitative reverse transcriptase PCR (RT-qPCR) was used to detect the expression of ABCG1 and ABCA1 mRNA in the liver. The expression of ABCG1 and ABCA1 protein was detected by Western blotting (WB). After 4 weeks of high-fat diet, the levels of TC, TG, and LDL-C in the mouse were increased, and the HDL-C level was decreased. After treatment with Alisol A 24-acetate, the levels of TC, TG, and LDL-C in the blood of hyperlipidemic mouse were significantly reduced, and the level of HDL-C was increased. The results of H&E staining showed that the lipid deposition in the liver of hyperlipidemic mouse was improved after treatment with Alisol A 24-acetate. RT-qPCR and WB analysis documented that ABCG1 and ABCA1 mRNA and protein expression in hyperlipidemic mice were promoted after the Alisol A 24-acetate treatment. In conclusion, Alisol A 24-acetate effectively alleviates the liver lipid deposition in hyperlipidemic mice, and this effect is achieved mostly by promoting the expression of ABCG1 and ABCA1 at the mRNA and protein levels.